The U.S. Federal Reserve cut interest rates by 25 basis points last week, but that may not have been the biggest news to bitcoin (BTC) bulls. The real surprise was the central bank's announcement to start buying $40 billion in short-term U.S. Treasury bills. That sparked a bullish frenzy in the crypto community, and why not? These purchases will expand the Fed's balance sheet, much as the 2020 Covid-era quantitative easing (QE) program and the post-global financial crisis maneuvers that fueled unprecedent ...

As of Dec. 17, 2025, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

As of Dec. 17, 2025, three stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying CRM stock? Here’s what analysts think: Read This Next: Photo via Shutterstock ...

I gave a hold rating to Diageo PLC ( DGEAF ) in June, as I wanted to see more signs of recovery, especially in the core spirits segment, and hence, I believed one should just wait andI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in buying quality companies at a discount to their intrinsic ...

I am focused on growth and dividend income. My personal strategy revolves around setting myself up for an easy retirement by creating a portfolio which focuses on compounding dividend income and growth. Dividends are an intricate part of my strategy as I have structured my portfolio to have monthly dividend income which grows through dividend reinvestment and yearly increases. Feel free to reach out to me on Seeking AlphaAnalyst’s Disclosure:I/we have a beneficial long position in the shares of STWD either ...

Micron Technology, Inc. (NASDAQ:MU) will release earnings results for its first quarter after the closing bell on Wednesday, Dec. 17.Analysts expect the company to report quarterly earnings at $3.93 per share, up from $1.79 per share in the year-ago period. The consensus estimate for Micron’s quarterly revenue is $12.81 billion, compared to $8.71 billion a year earlier, according to data from Benzinga Pro.The estimated revenue would mark a new record for the company, surpassing the $11.31 billion reported i ...

Core Insights - Recent secondary offerings from biotech companies Immunovant Inc. and Kymera Therapeutics Inc. have been observed, indicating a trend in the sector [1] Company Summaries - Immunovant Inc. has engaged in a secondary offering, which may impact its capital structure and investor sentiment [1] - Kymera Therapeutics Inc. has also participated in a secondary offering, reflecting its strategic financial decisions within the current market environment [1]

Core Insights - VolitionRx Limited has made significant progress in 2025, focusing on the commercialization of its Nu.Q® platform for human diagnostics, with key milestones achieved in cancer and sepsis detection [2][3][4] Group 1: Business Developments - The company received its first order for Nu.Q® Cancer assays for clinical certification in lung cancer and included the Nu.Q® NETs assay in a government-backed program in France for early sepsis detection, valued at approximately $7.3 million [3][4] - Volition signed two licensing agreements with major companies, Werfen and Hologic, marking a strategic move into the human diagnostics market [5] - The company is in discussions with around 10 leading diagnostic and liquid biopsy companies to secure additional licensing agreements, anticipating announcements throughout 2026 [6][7] Group 2: Financial Opportunities - The Total Addressable Markets (TAMs) for Volition's technologies are substantial, including $2.3 billion for lung cancer screening, $23 billion for multi-cancer early detection, and $2.8 billion for sepsis early detection [11] - The company aims to replicate its successful licensing strategy in the veterinary market within the human diagnostics space, with potential for diverse deal structures and recurring revenue [7][10] Group 3: Scientific and Clinical Progress - Volition's Nu.Q® NETs assay is being evaluated in over 20 hospitals across 10 countries for various clinical use cases, indicating its potential to become a routine blood test [8] - The company has achieved significant scientific advancements, including the development of a lateral flow test for quantifying nucleosomes, which aids in clinical decision-making [10] - A large-scale study demonstrated that the Nu.Q® NETs H3.1 biomarker is an independent predictor of mortality in sepsis patients, showcasing the assay's clinical relevance [10]

Micron Technology, Inc. (NASDAQ:MU) will release earnings results for its first quarter after the closing bell on Wednesday, Dec. 17.Analysts expect the company to report quarterly earnings at $3.93 per share, up from $1.79 per share in the year-ago period. The consensus estimate for Micron’s quarterly revenue is $12.81 billion, compared to $8.71 billion a year earlier, according to data from Benzinga Pro.The estimated revenue would mark a new record for the company, surpassing the $11.31 billion reported i ...